Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 18

1443P - Association between fruquintinib-induced hypertension and clinical outcomes from FRUTIGA, a phase III study of fruquintinib plus paclitaxel in previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

Date

14 Sep 2024

Session

Poster session 18

Topics

Clinical Research

Tumour Site

Gastric Cancer;  Gastro-Oesophageal Junction Cancer

Presenters

Shukui Qin

Citation

Annals of Oncology (2024) 35 (suppl_2): S878-S912. 10.1016/annonc/annonc1603

Authors

S. Qin1, R. Xu2, F. Wang3, L. Shen4, W. Guo5, T. Liu6, J. Li7, Y. Bai8, Z. Chen9, J. Wang10, Y. Pan11, Y. Shu12, F. Zhao13, Y. Cheng14, F. Ye15, K. Gu16, T. Zhang17, H. Pan18, Q. Liu19, S. Fan20

Author affiliations

  • 1 Oncology Dept., Chinese People's Liberation Army Cancer Center of Nanjing Bayi Hospital, 210002 - Nanjing/CN
  • 2 Department Of Medical Oncology, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 3 Medical Oncology Dept, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 4 Department Of Gastrointestinal Oncology, Key Laboratory Of Carcinogenesis And Translational Research (ministry Of Education/beijing), Peking University Cancer Hospital & Institute, 100142 - Beijing/CN
  • 5 Medical Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 6 Oncology Dept., Zhongshan Hospital of Fudan University, 200032 - Shanghai/CN
  • 7 Oncology Department, Tongji University Shanghai East Hospital, 200120 - Shanghai/CN
  • 8 Oncology Dept., Harbin Medical University Cancer Hospital, 150081 - Harbin/CN
  • 9 Oncology Dept., The Second Affiliated Hospital of Anhui Medical University, 230601 - Hefei/CN
  • 10 Internal Medicine-digestive Oncology Dept, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, 450008 - Zhengzhou/CN
  • 11 Oncology Department, The First Affiliated Hospital of USTC/ Anhui Provincial Hospital, 230001 - Hefei/CN
  • 12 Department Of Oncology, Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, 210029 - Nanjing/CN
  • 13 Oncology Dept., The First Affiliated Hospital of Bengbu Medical College, 233004 - Bengbu/CN
  • 14 Medical Oncology Department, Jilin Cancer Hospital, 130000 - Changchun/CN
  • 15 Medical Oncology Dept., The First Affiliated Hospital of Xiamen University, 361003 - Xiamen/CN
  • 16 Oncology Dept., The First Affiliated Hospital of Anhui Medical University, 230032 - Hefei/CN
  • 17 Oncology Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology/ Cancer Center Union Hospital, 430022 - Wuhan/CN
  • 18 Medical Oncology Department, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, 310016 - Hangzhou/CN
  • 19 C&r, HUTCHMED Limited, 968365 - Shanghai/CN
  • 20 C&r, HUTCHMED Limited, 201203 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1443P

Background

Hypertension is a common adverse drug reaction of using angiogenesis inhibitors targeting the vascular endothelial growth factor pathway, such as bevacizumab or ramucirumab. Moreover, angiogenesis inhibitor-induced hypertension is associated with improved clinical outcomes in various cancers. Here, we retrospectively analyzed these data from FRUTIGA to evaluate whether clinical outcomes were associated with fruquintinib-induced hypertension in advanced G/GEJ adenocarcinoma patients treated with fruquintinib plus paclitaxel.

Methods

FRUTIGA was a randomized, double-blind, placebo-controlled phase 3 study. The treatment arm was given fruquintinib 4 mg orally, once daily for 3 weeks followed by 1 week off, plus paclitaxel 80 mg/m2 intravenously on days 1/8/15 per cycle. Post hoc analyses were conducted in the treatment arm.

Results

351 patients were randomized to fruquintinib plus paclitaxel treatment arm. Among these patients, 59 (16.8%) experienced fruquintinib-induced hypertension. 23 (6.6%) experienced grade 3 or more fruquintinib-induced hypertension. No patient permanently discontinued due to hypertension. These patients had a better clinical outcome than those with no occurrence of fruquintinib-induced hypertension, with higher objective response rates (ORR) of 57.6% (95% CI 44.1%-70.4%) versus 39.4% (95% CI 33.7%-45.2%) (p=0.0136). Progression-free survival (PFS) and overall survival (OS) were 8.08 months (95% CI 6.4-8.3) (p=0.0003) and 11.80 months (95% CI 9.3-16.2) (p=0.0157) in the fruquintinib-induced hypertension group, versus 4.63 months (95% CI 4.6-5.9) and 9.36 months (95% CI 8.4-10.4) in no fruquintinib-induced hypertension group, respectively.

Conclusions

Fruquintinib-induced hypertension was associated with higher ORR, longer PFS and OS in advanced G/GEJ adenocarcinoma patients. The fruquintinib-induced hypertension could potentially be predictive of clinical outcomes for pts with treatment with fruquintinib plus paclitaxel.

Clinical trial identification

NCT03223376.

Editorial acknowledgement

Legal entity responsible for the study

Hutchmed Limited.

Funding

The National Science and Technology Major Project (project no. 2019ZX09301012), the Science and Technology Commission of Shanghai Municipality (Science, Technology and Innovation Action Plan, project no. 17431900100) and Hutchmed Limited.

Disclosure

Q. Liu, S. Fan: Financial Interests, Personal, Full or part-time Employment: Hutchmed Limited. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.